The Hôpital du Sacré-Cœur de Montréal is a hospital in the Cartierville neighbourhood of Montreal, Quebec, Canada, bordering on Saint-Laurent. It is one of the largest teaching hospitals affiliated with the Université de Montréal, and one of the largest hospitals in Quebec.

There are 554 beds in Hopital du Sacre-Coeur de Montreal.

During the past decade, Hopital du Sacre-Coeur de Montreal conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 46 clinical trials were completed, i.e. on average, 51.7% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 14 clinical trials were completed. i.e. 41.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital du Sacre-Coeur de Montreal" #1 sponsor was "Hopital du Sacre-Coeur de Montreal" with 21 trials, followed by "NCIC Clinical Trials Group" with 11 trials sponsored, "Ottawa Hospital Research Institute" with 9 trials sponsored, "Celgene" with 8 trials sponsored and "Université de Montréal" with 8 trials sponsored. Other sponsors include 159 different institutions and companies that sponsored additional 105 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital du Sacre-Coeur de Montreal" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 37 trials as a collaborator, "Canadian Critical Care Trials Group" with 8 trials as a collaborator, "National Cancer Institute (NCI)" with 8 trials as a collaborator, "Hopital du Sacre-Coeur de Montreal" with 7 trials as a collaborator and "NCIC Clinical Trials Group" with 7 trials as a collaborator. Other collaborators include 234 different institutions and companies that were collaborators in the rest 164 trials.

According to Clinical.Site data, the most researched conditions in "Hopital du Sacre-Coeur de Montreal" are "Atrial Fibrillation" (14 trials), "Coronary Artery Disease" (14 trials), "Asthma" (11 trials), "Breast Cancer" (7 trials) and "Colorectal Cancer" (6 trials). Many other conditions were trialed in "Hopital du Sacre-Coeur de Montreal" in a lesser frequency.

Most popular intervention types in "Hopital du Sacre-Coeur de Montreal" are "Drug" (115 trials), "Other" (37 trials), "Device" (31 trials), "Procedure" (31 trials) and "Biological" (19 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "placebo" (7 trials), "Apixaban" (4 trials), "Carboplatin" (4 trials) and "Rituximab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hopital du Sacre-Coeur de Montreal" are 204 trials for "All" genders, 16 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 54 active trials in "Hopital du Sacre-Coeur de Montreal". 1 are not yet recruiting, 24 are recruiting, 26 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 124 completed trials in Hopital du Sacre-Coeur de Montreal, 2 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital du Sacre-Coeur de Montreal, 3 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 77 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 23 trials, and there were also 53 trials that are defined as “Not Applicable".